Abstract
Single-cell cell cycle analysis is an emerging technique that requires detailed exploration of the image analysis process. In this study, we established a microfluidic single-cell cell cycle analysis method that can analyze cells in small numbers and in situ on a microfluidic chip. In addition, factors that influenced the analysis were carefully investigated. U87 or HeLa cells were seeded and attached to microfluidic channels before measurement. Cell nucleic DNA was imaged by 4′-6-diamidino-2-phenylindole (DAPI) staining under a fluorescent microscope and subsequently fluorescent intensities of the cell nuclei DNA were converted to depict histograms for cell cycle phases. DAPI concentration, microscopic magnification, exposure time and cell number were examined for optimal cell cycle analysis conditions. The results showed that as few as a few hundred cells could be measured by DAPI staining in the range of 0.4–0.6 μg/mL to depict histograms with typical cell cycle phase distribution. Microscopic magnification during image acquisition, however, could distort the phase distribution. Exposure time did not significantly affect the cell cycle analysis. Furthermore, cell cycle inhibitor rapamycin treatment changed the cell cycle phase distribution as expected. In conclusion, a method for microfluidic single-cell cell cycle analysis of spread cells in situ was developed. Factors such as dye concentration and microscopic magnification had more influence on cell cycle phase distribution. Further studies will focus on detail differentiation of cell cycle phases and the application of such a method for biological meanings.
Highlights
Aberrant cell cycle progression is a hallmark of cancer, it has been widely studied in cancer research [1]
New specific CDK4/6 inhibitors for the treatment of hormone receptor (HR)-positive breast cancers are in phase III trials and palbociclib received fast-track approval by the Food and Drug Administration (FDA) earlier in 2015 [2]
By using fully-spread cells, adherent cells were minimally disturbed before cell cycle analysis
Summary
Aberrant cell cycle progression is a hallmark of cancer, it has been widely studied in cancer research [1]. Recent advances have reinforced targeting cell cycle for cancer treatment. New specific CDK4/6 inhibitors for the treatment of hormone receptor (HR)-positive breast cancers are in phase III trials and palbociclib received fast-track approval by the Food and Drug Administration (FDA) earlier in 2015 [2]. Cyclin dependent kinases (CDKs) 4 and 6 are key regulators for G1-S transition. Previous therapeutic applications of CDK4/6 inhibitors failed due to their toxicity. The new Micromachines 2017, 8, 36; doi:10.3390/mi8020036 www.mdpi.com/journal/micromachines
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.